tRF-Leu reverse breast cancer cells chemoresistance by regulation of BIRC5.

Autor: Sun L; Hepatopancreatobiliary Surgery Department, The Third Affiliated Hospital of Soochow University, Changzhou First People's Hospital, Changzhou, China.; Department of General Surgery, The Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University, Changzhou, China., Jiao YW; Department of General Surgery, The Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University, Changzhou, China., Cui FQ; Department Graduate School of Dalian Medical University, Dalian Medical University, Dalian, China., Liu J; Department Graduate School of Dalian Medical University, Dalian Medical University, Dalian, China., Xu ZY; Children's Hospital of Nanjing Medical University, Nanjing, China. xuzhya@njmu.edu.cn., Sun DL; Hepatopancreatobiliary Surgery Department, The Third Affiliated Hospital of Soochow University, Changzhou First People's Hospital, Changzhou, China. 20225235066@stu.suda.edu.cn.
Jazyk: angličtina
Zdroj: Discover oncology [Discov Oncol] 2024 Sep 15; Vol. 15 (1), pp. 449. Date of Electronic Publication: 2024 Sep 15.
DOI: 10.1007/s12672-024-01317-1
Abstrakt: Objective: Accumulating studies reported the crucial roles of tRFs in tumorigenesis. However, their further mechanisms and clinical values remains unclear. This study aimed at the further investigation of tRF-Leu in breast cancer chemotherapy resistance.
Methods: The high-throughput sequencing was performed and identified the downregulation of tRF-Leu in MCF7/ADR cells. The function of tRF-Leu in breast cancer cells and breast cancer chemotherapy resistance was investigated in vitro and in vivo, including colony formation assay, CCK-8 assay, transwell assay and apoptosis assay. The binding site of tRF-Leu on BIRC5 was verified by dual-luciferase assay.
Results: tRF-Leu was downregulated in MCF7/ADR cells. Overexpression of tRF-Leu inhibited the migration of breast cancer cells. Furthermore, tRF-Leu could reverse the resistance of MCF7/ADR cells to Adriamycin both in vitro and in vivo. BIRC5 was a target of tRF-Leu, which might be involved in the chemotherapy resistance regulation.
Conclusion: We demonstrated that tRF-Leu could inhibit the chemotherapy resistance of breast cancer by targeting BIRC5. These findings might identify new biomarkers of breast cancer therapy and bring new strategies to reverse chemotherapy resistance.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: